The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Open accessAbstract
As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing and their impact on individual patients and health care policies, and argues for the need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STIGLITZ, J. (2013) · New Perspectives Quarterly · doi:10.1111/npqu.11358 · Cited by 1,447
Medical Bankruptcy in the United States, 2007: Results of a National Study
Himmelstein, D. U., Thorne, D., Warren, E., & Woolhandler, S. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.04.012 · Cited by 805
Gambacorti-Passerini, C., Antolini, L., Mahon, F.-X., Guilhot, F., Deininger, M., Fava, C., Nagler, A., Della Casa, C. M., Morra, E., Abruzzese, E., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr060 · Cited by 429
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question
Fojo, T., & Grady, C. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp177 · Cited by 349
Huang, X., Cortes, J., & Kantarjian, H. (2012) · Cancer · doi:10.1002/cncr.26679 · Cited by 300
Pharmaceutical research and development: what do we get for all that money?
Light, D. W., & Lexchin, J. R. (2012) · BMJ · doi:10.1136/bmj.e4348 · Cited by 258
Björkholm, M., Ohm, L., Eloranta, S., Derolf, Å., Hultcrantz, M., Sjöberg, J., Andersson, T., Höglund, M., Richter, J., Landgren, O., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7146 · Cited by 211
An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard
Lee, C. P., Chertow, G. M., & Zenios, S. A. (2009) · Value in Health · doi:10.1111/j.1524-4733.2008.00401.x · Cited by 196
The $800 million pill: the truth behind the cost of new drugs
(2005) · Choice Reviews Online · doi:10.5860/choice.42-5898 · Cited by 133
Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009
Chen, Y., Wang, H., Kantarjian, H. M., & Cortes, J. E. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.745525 · Cited by 127
Cited by
Carrera, P. M., Kantarjian, H. M., & Blinder, V. S. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21443 · Cited by 876
The NLRP3 inflammasome in acute myocardial infarction
Toldo, S., & Abbate, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.161 · Cited by 665
Essential medicines for universal health coverage
Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., Gyansa-Lutterodt, M., Jing, S., Luiza, V. L., Mbindyo, R. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31599-9 · Cited by 661
Prasad, V., & Mailankody, S. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.3601 · Cited by 503
Pricing in the Market for Anticancer Drugs
Howard, D. H., Bach, P. B., Berndt, E. R., & Conti, R. M. (2015) · Journal of Economic Perspectives · doi:10.1257/jep.29.1.139 · Cited by 444
Metadata
- Authors
- Leukemia, E. I. C. M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-05-30
- Volume
- 121
- Issue
- 22
- Pages
- 4439-4442
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2112942078
- Cited by
- 592
- References
- 13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. https://app.cochat.ai/papers/10.1182/blood-2013-03-490003
- The paper
- Leukemia, E. I. C. M. (2013). The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. https://doi.org/10.1182/blood-2013-03-490003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.